Current Affairs - Technology - Discussion

BIRSA 101 is India’s first fully indigenous CRISPR-based gene therapy developed to treat Sickle Cell Disease (SCD), marking a major milestone in the nation’s genomic medicine capabilities. Launched by Dr. Jitendra Singh and dedicated to Birsa Munda on his 150th anniversary, the therapy represents a significant step toward India’s mission to eliminate SCD. It is designed as a low-cost alternative to global treatments that currently cost ₹20–25 crore, making advanced gene therapy accessible to a wider population. This innovation strengthens public health efforts while boosting India’s position in advanced biomedical research and healthcare technology.